VCNX Stock Overview

A clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. More details

VCNX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 11.3% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($2M)

Makes less than USD$1m in revenue ($601K)

Negative shareholders equity

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Vaccinex, Inc. Competitors

AXIM Biotechnologies

OTCPK:AXIM

US$2.7m

Silo Pharma

NasdaqCM:SILO

US$3.4m

Aditxt

NasdaqCM:ADTX

US$2.6m

Ensysce Biosciences

NasdaqCM:ENSC

US$3.6m

Price History & Performance

Summary of share price highs, lows and changes for Vaccinex
Historical stock prices
Current Share Price	US$0.67
52 Week High	US$8.90
52 Week Low	US$0.25
Beta	1.35
1 Month Change	11.00%
3 Month Change	-40.54%
1 Year Change	-88.99%
3 Year Change	-99.75%
5 Year Change	-99.92%
Change since IPO	-99.97%

Recent updates

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Aug 17

Shareholder Returns

	VCNX	US Biotechs	US Market
7D	-26.0%	2.8%	3.0%
1Y	-89.0%	-6.8%	10.1%

Return vs Industry: VCNX underperformed the US Biotechs industry which returned -6.8% over the past year.

Return vs Market: VCNX underperformed the US Market which returned 10.1% over the past year.

Price Volatility

Is VCNX's price volatile compared to industry and market?
VCNX volatility
VCNX Average Weekly Movement	38.7%
Biotechs Industry Average Movement	11.7%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	4.1%

Stable Share Price: VCNX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VCNX's weekly volatility has increased from 27% to 39% over the past year.

About the Company

Founded	Employees	CEO	Website
2001	25	Maurice Zauderer	www.vaccinex.com

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer’s disease and has completed phase 2 study for treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer.

Vaccinex, Inc. Fundamentals Summary

How do Vaccinex's earnings and revenue compare to its market cap?
VCNX fundamental statistics
Market cap	US$1.78m
Earnings (TTM)	-US$18.63m
Revenue (TTM)	US$601.00k

3.0x

P/S Ratio

-0.1x

P/E Ratio

Is VCNX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VCNX income statement (TTM)
Revenue	US$601.00k
Cost of Revenue	US$12.55m
Gross Profit	-US$11.94m
Other Expenses	US$6.69m
Earnings	-US$18.63m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-6.96
Gross Margin	-1,987.35%
Net Profit Margin	-3,100.50%
Debt/Equity Ratio	-1.0%

How did VCNX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/04 23:00
End of Day Share Price	2025/05/02 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vaccinex, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Shrader	BTIG
Matthew Kaplan	Ladenburg Thalmann & Company
Leland Gershell	Oppenheimer & Co. Inc.

VCNX Stock Overview

Rewards

Risk Analysis

Vaccinex, Inc. Competitors

OTCPK:AXIM

US$2.7m

NasdaqCM:SILO

US$3.4m

NasdaqCM:ADTX

US$2.6m

NasdaqCM:ENSC

US$3.6m

Price History & Performance

Recent News & Updates

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex, Inc. announced delayed annual 10-K filing

Vaccinex, Inc. Files Form 15

Vaccinex, Inc. Intends to Delist Common Stock from Nasdaq

Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index

Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index

Recent updates

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex, Inc. announced delayed annual 10-K filing

Vaccinex, Inc. Files Form 15

Vaccinex, Inc. Intends to Delist Common Stock from Nasdaq

Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index

Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index

Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.

Vaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, Spain

Vaccinex Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

New major risk - Financial position

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S Disease

Insufficient new directors

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Vaccinex, Inc. announced that it has received $1.75 million in funding

Vaccinex, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022)

Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding

Vaccinex, Inc. has filed a Follow-on Equity Offering.

Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital Market

Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding

New major risk - Market cap size

New major risk - Financial position

Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Vaccinex Receives Non-Compliance Notice From Nasdaq

Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs

Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study

Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Vaccinex, Inc. Provides Nasdaq Compliance Update

Vaccinex, Inc. announced that it has received $0.65 million in funding

New major risk - Financial position

New minor risk - Share price stability

Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co.

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Insufficient new directors

Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of Cancer

Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid Requirement

First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021)

Insufficient new directors

Vaccinex, Inc., Annual General Meeting, May 12, 2022

Vaccinex, Inc. announced that it expects to receive $6.599997 million in funding

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Price target decreased to US$7.00

Vaccinex, Inc.(NasdaqCM:VCNX) dropped from Russell Microcap Value Index

Vaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease

Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDA

Shareholder Returns

Price Volatility

About the Company

Vaccinex, Inc. Fundamentals Summary

3.0x

-0.1x

Earnings & Revenue

Company Analysis and Financial Data Status